Keyur Parekh: Hi. Thank you for taking my questions. Hopefully, you can hear me okay. Paul, just a big picture one for you on capital allocation structure strategy. I know you’ve been asked this before on the call, but just kind of between, Horizon, I think reports — press reports earlier in kind of last week talking about potentially exploring a merger with Haley and for the consumer health business. Just a little bit of a speed on how you are thinking about the shape of the overall group, where you think it makes sense for you to kind of flex your balance sheet, and how you are thinking about areas of priorities over the next kind of 6 to 12 months? And then separately on kind of the BOI kind of guidance or kind of how we should think about BOI into 2023 or into ’25? Given the Aubagio kind of hit in 2023, are you still expecting BOI to grow in ’23 over ’22?
Paul Hudson: Okay. Keyur, thank you. J-B, I’ll give you the BOI question. On the capital allocation, we’ve been clean from 2019 saying that we’re looking to add science where we can. We’ve done 25 BD and M&A deals. I think as JB said, we’re not scared to leverage the balance sheet. You saw it’s public. We were in play for Horizon, last year, it was opportunistic for us. If you remember that Q2 was disappointing on execution, and we’re brilliant in rare. We figured it was a good fit. We could make it work and it would unleash some things for us. So, you should know that we’re not conservative if we think we can create more value for patients, for shareholders and for ourselves as a company, no hesitation. The gossip around Consumer, it makes me smile because we’re running a really great Consumer business, but I wouldn’t be misled by that. We’re very proud of what we’re doing in Consumer. J-B?
Jean-Baptiste de Chatillon: Yes. Well, as we mentioned during this call, there are several drivers which are helping us in our trajectory to ’25. Of course, the Dupixent spectacular growth is accretive and has been accelerated with the acceleration of the reimbursement of the development balance with Regeneron. But I mentioned also the COGS improvement that we are working on. I could mention also some royalties. We said you could calculate looking at fitusiran projections, the products on which we have significant royalties. So we have on top of the performance of the efficiencies, we go on working on the underlying business. Yes, we will go across the Aubagio LoE in ’23 with an EPS guidance at constant exchange rate, which is low single digit, which I think makes it quite easy to see what it can look like in terms of BOI. So, you see we are on our trajectory to ’25, and we have multiple drivers to get there.
Operator: Last question from Richard Parkes from Exane.
Richard Parkes: Firstly, on flu vaccine, I just wanted to ask it a bit different way. Could you talk about how much performance this year was depressed by lower vaccine uptake, just so we can get a better understanding of how a rebound next year, maybe you could talk about the kind of levels of returns, et cetera. And then secondly, just sorry to push on the consumer again. Can you just update us where you are in terms of the Tamiflu Cialis OTC switch studies. I think there were some ongoing discussions over the clinical protocol for the Cialis trial. So I wondered if that was resolved. There’s a perception out there that progress of those trials is a gating factor to whether a consumer will stay within the Sanofi Group longer term? So maybe — I don’t know if you can comment on that.
Paul Hudson: Okay. Thank you. So Thomas, this is the last question. So flu.
